Badros, Ashraf

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.

Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 812

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 721

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

Kumar, S. K., Dimopoulos, M. A., Kastritis, E., Terpos, E., Nahi, H., Goldschmidt, H., Hillengass, J., Leleu, X., Beksac, M., Alsina, M., et al. (2017) · Leukemia

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 351

Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma

Badros, A., Hyjek, E., Ma, N., Lesokhin, A., Dogan, A., Rapoport, A. P., Kocoglu, M., Lederer, E., Philip, S., Milliron, T., et al. (2017) · Blood

Multiple Myeloma Research and TreatmentsCancer Immunotherapy and Biomarkers

Cited by 197

Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations

Rosiñol, L., Beksac, M., Zamagni, E., Van de Donk, N. W. C. J., Anderson, K. C., Badros, A., Caers, J., Cavo, M., Dimopoulos, M., Dispenzieri, A., et al. (2021) · British Journal of Haematology

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 179

Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study

Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A., Callander, N., Sborov, D., Suvannasankha, A., et al. (2021) · Cancer

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 144

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

Lonial, S., Popat, R., Hulin, C., Jagannath, S., Oriol, A., Richardson, P. G., Facon, T., Weisel, K., Larsen, J. T., Minnema, M. C., et al. (2022) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 101

Hypothyroidism in patients with multiple myeloma following treatment with thalidomide

Badros, A. Z., Siegel, E., Bodenner, D., Zangari, M., Zeldis, J., Barlogie, B., & Tricot, G. (2002) · The American Journal of Medicine

Multiple Myeloma Research and TreatmentsThyroid Disorders and Treatments

Cited by 83

Single‐agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM‐2 trial

Nooka, A. K., Cohen, A. D., Lee, H. C., Badros, A., Suvannasankha, A., Callander, N., Abdallah, A., Trudel, S., Chari, A., Libby, E. N., et al. (2023) · Cancer

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 73

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma

Sklavenitis-Pistofidis, R., Aranha, M. P., Redd, R. A., Baginska, J., Haradhvala, N. J., Hallisey, M., Dutta, A. K., Savell, A., Varmeh, S., Heilpern-Mallory, D., et al. (2022) · Cancer Cell

Multiple Myeloma Research and TreatmentsCancer Immunotherapy and Biomarkers

Cited by 70

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

Holkova, B., Zingone, A., Kmieciak, M., Bose, P., Badros, A. Z., Voorhees, P. M., Baz, R., Korde, N., Lin, H.-Y., Chen, J.-Q., et al. (2016) · Clinical Cancer Research

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 48

Abstract 4701: NY-ESO T cells administered post ASCT for MM exhibit extended functionality without exhaustion in a natural pattern of effector and memory programming

Rapoport, A., Stadtmauer, E., Melchiori, L., Wong, R., Davila, E., Binder-Scholl, G., Holdich, T., Vogl, D., Weiss, B., Finkelstein, J., et al. (2015) · Cancer Research

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 1